Atlas Trials

Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting

Clinical trial NCT02184416 · COMPLETED

Trial details

NCT number
NCT02184416
Sponsor
Pfizer
Status
COMPLETED
Study type
OBSERVATIONAL
Metastatic Renal Cell Carcinoma (mRCC)
Start date
2014-10-31
Primary completion
2022-09-30
Enrollment
554

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.